Since Lisa’s last treatment, the drug T-DM1 has been getting a lot of positive press due to the encouraging results of the Emilia clinical trial reported at the recent meeting of the American Society for Clinical Oncology in Chicago. This is the same drug that Lisa is receiving. She is part of a new phase III clinical trial the results of which will be reported in a year or so.
For a very good, albeit rather dry, description of T-DM1, check out this YouTube video:
The clinical trial protocol requires frequent tests and scans to evaluate effectiveness. Therefore, Lisa had an echo-cardiogram and CT scans last Thursday. On Friday we met with her oncologist’s nurse practitioner to discuss the scan results before being approved for her third T-DM1 infusion.
The echo-cardiogram showed that her heart function (ejection fraction) has not been affected by the treatment and has actually improved a little.
The CT scans showed that her disease is “stable”, which means that it has not increased in size anywhere and there are no new disease sites. The tumors in her parotid glands continue to decrease in size.
These were the results that we had hoped for and she got the green light for her third infusion. Even though it was another long day at MGH, were back home in time to catch some of the US Open!
Lisa seems to have tolerated this treatment better than the previous two. Yesterday, she enjoyed watching the girls compete in the first horse show of the season. Then, later in the afternoon, we took her on a trip around the lake in the new paddle boat!
Her next treatment will be in three weeks. Enjoy the rest of June!